Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-
Introduction Genome-scale DNA sequence information offers potential molecular targets Newly developed genomic technologies promise to impact all facets of the drug discovery
Target-based drug discovery
Challenges of New Drug Discovery Need for new antibiotic discovery A mechanism that contributes to antibiotic resistance is drug exclusion by efflux systems
Challenges of New Drug Discovery Desirable properties of antimicrobial targets Antimicrobial targets should meet the criteria of spectrum, selectivity, functionality, and essentiality ① provide adequate spectrum and selectivity ② essential for growth or viability of the pathogen ③ knowledge on the function is necessary in order to design assays and high-throughput screens
Mining genomes for antimicrobial drug targets Microbial Genomics and Drug Target Selection
Comparative genomics: target spectrum and selectivity Useful approach to estimate target spectrum and selectivity Offer the opportunity to develop broad-spectrum antibiotics Significant proportion of genomes encode proteins with no known function Microbial Genomics and Drug Target Selection
Genetic strategies: verifying the essentiality or expression of gene targets Combine molecular biology and common drug screening ↓ expediting the identification of antimicrobials with unique modes of action ① signature-tagged mutagenesis (STM) ② in vivo expression technology (IVET) ③ differential fluorescence induction (DFI) Microbial Genomics and Drug Target Selection
Microarray analysis: establishing function for new targets Identification of new regulatory pathways or networks ↓ design novel drugs Screen populations of clinical isolates or related strains (Used as a comparative genomics tool) ↓ conserved genes/genetic variation Microbial Genomics and Drug Target Selection
Determining Therapeutic Utility: Drug Target Screening and Validation Target-based drug screening Strain array for antibacterial discovery ○ any target ○ the molecular target can be confirmed with a functional assay ○ identify several compounds with good inhibitory activity ○ Strains be screened at any time and at low cost
Determining Therapeutic Utility: Drug Target Screening and Validation Target-based drug screening In silico screening and structure-based drug design
Determining Therapeutic Utility: Drug Target Screening and Validation Target-based drug screening Surrogate-ligand-based screening ○ Surrogate ligand: short peptides bind to functional sites of target proteins inhibiting target’s function ○ Important aspect: data of protein activity isn’t required identify active site of unknown function
Determining Therapeutic Utility: Drug Target Screening and Validation Microarrays and drug target validation Microarray analysis of inhibition of gene function ○ establish whether a putative target is required to generate the drug signature ○ Microarray analysis of inhibition may be useful for validation (a compound often may affect unintended components)
Using microarray-based gene expression profiling to identify an unknown toxicant’s mechanism of action
Genomics and Toxicology: The Emergence of Toxicogenomics Microarrays in mechanistic toxicology ToxBlot arrays: investigating toxicity processes ≒ 600 marker genes for array construction genes for toxicology Goal of toxicogenomics Identify groups of genes that are tightly correlated with known classes of toxicants
Genomics and Toxicology: The Emergence of Toxicogenomics Microarrays in predictive toxicology Goal : predict adverse drug reduce the time reduce expense
Summary Therapeutic inhibition will be done by target-based strategies which combine computational and experimental approaches Microarray-based gene expression profiling is becoming a standard in mechanistic toxicology and is providing important insights into the mechanisms of action Toxicogenomics is expected to impact the safety assessment of new drugs and to reduce the number of drug failures
Thank you for your attention